Effect of azathioprine on the cell cycle of haemopoietic cells

Area of Science:

• Hematology
• Immunosuppression
• Renal Transplantation

Background:

• Azathioprine is an immunosuppressive drug commonly used in organ transplant recipients.
• Megaloblastic anemia is a condition affecting red blood cell production.
• Renal transplant patients are susceptible to various drug-induced side effects.

Purpose of the Study:

• To investigate the specific cell cycle alterations in erythropoiesis associated with azathioprine treatment in renal transplant patients.
• To compare these changes with those observed in neutrophil development.

Main Methods:

• Analysis of peripheral blood cell populations in three azathioprine-treated renal transplant patients.
• Flow cytometry or similar cell cycle analysis techniques to assess cell cycle phase distribution (G2 phase).
• Differential counting of erythroblasts and neutrophil precursors.

Main Results:

• Megaloblastic erythropoiesis was observed in all three patients.
• A significant increase in early polychromatic erythroblasts within the G2 phase of the cell cycle was noted.
• A less pronounced increase in G2 phase cells was found in the neutrophil promyelocyte-myelocyte pool.

Conclusions:

• Azathioprine-induced megaloblastic erythropoiesis is associated with a specific disruption of the erythroblast cell cycle, particularly affecting the G2 phase.
• Neutrophil development appears less sensitive to this particular azathioprine-induced cell cycle perturbation.
• These findings highlight a potential mechanism for azathioprine's hematological toxicity in transplant recipients.